{Reference Type}: Journal Article
{Title}: Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014).
{Author}: González-Macías J;Del Pino-Montes J;Olmos JM;Nogués X; ;
{Journal}: Rev Clin Esp (Barc)
{Volume}: 215
{Issue}: 9
{Year}: Dec 2015
暂无{DOI}: 10.1016/j.rce.2015.08.003
{Abstract}: These guidelines update issues covered in previous versions and introduce new ones that have arisen in recent years. The former refer mainly to the therapeutic developments that have been made during this time (zoledronate, denosumab, bazedoxifene), which have led to a change in the drug selection algorithm. The latter deal with therapeutic management, the description of new adverse effects (which have led to changes in therapeutic behaviour patterns, as is the case with atypical fracture of the femur), treatment duration (with consideration for the so-called "therapeutic holidays"), the so-called sequential treatment and changes in treatment imposed by certain circumstances. A new algorithm has been introduced for sequential treatment. Attention has also been paid to vertebroplasty and kyphoplasty.